Seven clinically tested probiotics
- Promotes balanced intestinal microflora
- Enhances healthy digestion and immunity
- Reduces inflammation
- Contains seven probiotics clinically studied in humans
- Supports healthy cholesterol levels
$61.19 — or subscribe and save 20%
Advanced Biotics delivers seven probiotic strains which have been used clinically for over 50 years. Streptococcus thermophiles, one of the strains in this formula, absorbs cholesterol which lowers total cholesterol levels. Bifidobacterium longum balances the immune system to help manage allergies and also helps to prevent DNA damage, thereby reducing the risk of cancer. The other strains found in Advanced Biotics improve digestion, reduce inflammation and block harmful bacteria from colonizing the gastrointestinal tract and the genitourinary system.
Those who have taken antibiotics, people who suffer from various infections of the digestive tract, those with intestinal issues, or those looking to boost their immunity can benefit from Advanced Biotics.
AOR’s Advanced Biotics delivers seven unique and effective probiotic strains that have been used clinically for over 50 years to address a variety of health concerns outlined above.
AOR’s Advanced Biotics formula contains a blend of seven clinically tested probiotics that promote favourable gut flora and support gastrointestinal health.
Take one capsule one to four times a day and at least two to three hours before or after taking antibiotics.
AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, nuts, peanuts, sesame seeds, sulphites, mustard or eggs.
Consult a heath care practitioner prior to use if you have fever, vomiting, bloody diarrhea or severe abdominal pain. Discontinue use and consult a health care practitioner if symptoms of digestive upset (e.g. diarrhea) occur, worsen, or persist beyond 3 days. Do not use if you have an immune-compromised condition (e.g. AIDS, lymphoma, patients undergoing long-term corticosteroid treatment). This product has come into contact with gluten, corn, soy, dairy, and fish; do not use if you have such allergies.
- Antibiotic related diarrhea
- Atopic dermatitis
- Autoimmune diseases
- Irritable bowel syndrome
- Inflammatory bowel disease
- Yeast infection
The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.
† Colony-forming units
A combination of probiotics may have synergistic health effects, compared to the activity of a single probiotic. This randomized, double-blind, placebo-controlled clinical study looked at the effect of a cocktail of bifidobacterium bacteria in tackling allergic rhinitis and intermittent asthma in children (mean age 9 ± 2.2 years). The children were given either a placebo or a combination medication, containing Bifidobacteria mixture, B longum BB536 (3×109 CFU), B infantis M-63 (1×109 CFU), and B breve M-16 V (1×109 CFU) for 4 weeks and monitored for improvement of symptoms and quality of life. While the placebo group had worsening of symptoms during the trial, the treatment group showed significant improvement in symptoms and quality of life in children with pollen-induced allergic rhinitis and intermittent asthma.
A standalone study evaluated the effect of BB536 in relieving clinical symptoms and modulating cytokine levels with subjects with Japanese cedar pollinosis (JCPsis), during pollen season. A randomized, placebo-controlled, double-blind clinical study evaluated the role of Bifidobacterium longum BB536 in modulating symptoms of cedar pollinosis in patients, during pollen season. Participants consumed yogurt containing BB536 twice a day, beginning 4 weeks before the onset of pollen season and continuing for 14 weeks. Subjective symptoms and self-care measures were recorded daily and blood samples were taken before and during the intervention (at weeks 4, 9, and 14) to measure the blood parameter levels related to Japanese cedar pollinosis. Results show relief in nasal symptoms, such as itching, rhinorrhea, and blockage, as well as throat symptoms. A significant increase in interferon-γ and blood eosinophil rates was observed in the treatment group, compared to the placebo group, suggesting a modulatory effect on Th balance and a supporting role in allergic inflammation.
A randomized, prospective, double-blind, controlled trial was conducted in children, aged 2-5 years old to determine if Lactobacillus casei could be used to improve the health status of preschool children suffering from allergic asthma and/or allergic rhinitis, over a 12-month period. The children received either fermented milk containing L. casei (1×108 CFU/mL) or strain-free fermented milk. The time free from and the number of episodes of asthma/rhinitis after starting intervention were the outcome measures.
In children with rhinitis, the annual number of rhinitis episodes was lower in the intervention group; the mean duration of diarrhea episodes was lower in the intervention groups, suggesting that long-term supplementation with L. casei in children could be used to improve the health status of allergic rhinitis.
This study assessed the effect of a combination of bifidobacterium strains in children with Irritable Bowel Syndrome (IBS). This double-blind, placebo-controlled, crossover study randomized 48 children with IBS to receive either a placebo or a mixture of B. longum BB536, B. infantis M-63 and B. breve M-16V for 6 weeks, followed by a 2-week washout period and crossover for another 6 weeks of supplementation. Subjects were evaluated for abdominal pain symptoms and quality of life.
The results show that bifidobacterium supplementation led to a complete resolution of abdominal pain and improved abdominal pain frequency in a significantly higher proportion of children, compared to the placebo group.
This randomized, double‐blinded, placebo‐controlled trial was aimed at investigating the effect of BB536 supplementation in patients with active ulcerative colitis (UC). 56 patients with mild to moderate UC were randomized to receive BB536 at 2-3×1011 CFU per day or placebo for 8 weeks. Results show clinical remission at 8 weeks in 63% of the supplementation group, compared to 52% in the placebo group, with a significant decrease in the Rachmilewitz endoscopic index (EI) and the Mayo subscore at week 8 in the BB536 group, suggesting that BB536 improved clinical symptoms and endoscopic findings in patients with mild to moderately active UC.
This randomized, placebo-controlled trial evaluated the effect of a combination of probiotics in alleviating small intestinal bacterial overgrowth (SIBO) and permeability in chronic liver disease. Patients with chronic liver disease were randomized to receive either a placebo or six bacterial strains: Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus rhamnosus, and Streptococcus thermophilus – for 4 weeks. After supplementation, changes in the composition of fecal bacteria, SIBO, intestinal permeability, and clinical symptoms were examined. The results show a disappearance of SIBO in many subjects in the probiotic group, compared to the placebo group – which had no reduction or disappearance of SIBO. General gastrointestinal symptoms also improved significantly in the probiotic group and although there was an improvement in intestinal permeability, the authors report that this improvement was not significant, when compared to the control group. These results led the authors to conclude that short term probiotic use can be useful in alleviating SIBO and its clinical symptoms.
This study aimed to identify the best probiotic supplementation in a pediatric population with Helicobacter pylori infections, through a systematic review and network meta-analysis. Twenty-nine trials (3122 participants) involving 17 probiotic regimens were identified. Compared with placebo, probiotic-supplemented triple therapy significantly increased H. pylori eradication rates. Lactobacillus casei was identified the best for H. pylori eradication rates. multi-strain of Bifidobacterium infantis, Bifidobacterium longum, L. acidophilus, L. casei, Lactobacillus plantarum, Lactobacillus reuteri, L. rhamnosus, Lactobacillus salivarius, Lactobacillus sporogenes, and Streptococcus thermophilus was the best to reduce the incidence of diarrhea. Multi-strain of B. longum, Lactobacillus bulgaricus, and S. thermophilus for constipation; multi-strain of Bifidobacterium bifidum, B. infantis, L. acidophilus, L. bulgaricus, L. casei, L. reuteri, and Streptococcus for taste disturbance and multi-strain of Bifidobacterium breve, B. infantis, L. acidophilus, L. bulgaricus, L. casei, L. rhamnosus, and S. thermophilus for nausea/vomiting.
This randomized single‐blind placebo‐controlled study evaluated the effect of a multistrain formulation of probiotics in patients with irritable bowel syndrome (IBS), without concurrent medication – all patients were required to stop their ongoing treatment for IBS a week before enrolment in the study. the formulation included the following strains: Streptococcus thermophilus [1.0 × 108 colony forming units(cfu)/mL], Lactobacillus bulgaricus (1.0 × 107 cfu/mL), Lactobacillus acidophilus (1.0 × 107 cfu/mL) and Bifidobacterium longum (1.0 × 107 cfu/mL) and participants were instructed to take this in milk or milk with no bacteria (placebo) for 4 weeks. The clinical symptoms were scored and intestinal permeability was measured by a triple sugar test before and after treatment. Following supplementation, the probiotic supplemented group showed a significant decrease in small bowel permeability, as well as a significant decrease in mean global IBS scores, compared with the baseline and the placebo group, suggesting that lactic acid bacterial strains are an effective option for diarhoea-predominant IBS improved mucosal barrier function.
The effect of BB536 on immunity is attributed to its role in modulating microbial crosstalk in the microbiome. In this randomized, double-blind, parallel, and placebo-controlled study, 529 pre-school children in Malaysia were given either BB536 (5×109 CFU) or placebo daily for 10 months, with 219 subjects fully complying to the trial requirements for over 10 months. Results show a significant difference in the mean number of times of respiratory illnesses over the duration of the study. Durations of sore throats were reduced by 46% and coughs were reduced by 16%, compared to the placebo groups. Gut flora diversity was also observed in the group taking BB536. Interestingly, this group has an abundance of Faecalibacterium, which is associated with anti-inflammation and immuno-modulation, in the BB536 supplemented group.
This a randomized, placebo-controlled, double-blind trial evaluated the effects of BB536 supplementation in elderly subjects for 5 weeks. 27 subjects were pre-administered at 1×1011 CFU daily for 5 weeks, during which they also received influenza vaccination at the 3rd-week mark, before randomization for 14 weeks. The results show a reduced proportion of subjects that contracted influenza and fevers in the treatment group, compared to the placebo group. Additionally, supplementation increased Natural Killer (NK) cell activity in the supplementation group, suggesting a potentiation of innate immunity, as well as a reduction in the incidence of influenza by BB536.
A separate study looking at similar markers in the elderly, showed a significant increase in NK cells activity during the intervention, as well as an increase in bifidobacterium fecal bacterium, suggesting that BB536 increases the cell number of bifidobacterium in intestinal microbiota and modulates immune function in the elderly.
Bifidobacterium longum BB536 is considered a multifunctional probiotic, effective in alleviating gastrointestinal, immunological and infectious diseases, with the ability to stabilize gut microbiota and improve the intestinal environment. This probiotic has been shown to improve immune dysfunction by promoting a homeostatic balance within the host-microbiome interaction. Research studies show that BB536 acts as a microbiome modulator, specifically by modulating luminal metabolism and stabilizing the gut microbiota.
Clinically, BB536 alleviates gastrointestinal disorders, improves the frequency of defecation and fecal characteristics in healthy adults with constipation, improves microbiome diversity, stimulates, modulates and enhances host immunity and alleviates nasal and ocular allergic symptoms and modulate the allergic immune response in patients sensitive to Japanese cedar pollens among other health benefits. This publication provides sufficient evidence for the use of BB536 as a supplement for immunity support and allergic reactions.
A randomized, placebo-controlled clinical trial assessed the effect of Lactobacillus casei on the composition and metabolic activities of intestinal microflora and immune parameters in healthy male subjects aged 40 – 65. Participants consumed fermented milk containing 1×109 CFU L. casei or a placebo daily for 4 weeks. Results show that the consumption of L. casei led to an increase in lactobacillus and bifidobacterium count in the faeces of participants. There was also a corresponding decrease in the counts of clostridium species, suggesting that L. casei is able to modulate the composition and metabolic activity of intestinal flora. Significant differences were not observed between the groups, on effects on natural killer cells or cytokine production, which may be attributed to the dose or duration of the study.